Cargando…

A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma

Kras-driven lung adenocarcinoma (LUAD) is the most common lung cancer. A significant fraction of patients with Kras-driven LUAD respond to immunotherapy, but mechanistic studies of immune responses against LUAD have been limited because of a lack of immunotherapy-responsive models. We report the dev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fitzgerald, Brittany, Connolly, Kelli A., Cui, Can, Fagerberg, Eric, Mariuzza, Dylan L., Hornick, Noah I., Foster, Gena G., William, Ivana, Cheung, Julie F., Joshi, Nikhil S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500377/ https://www.ncbi.nlm.nih.gov/pubmed/34632444 http://dx.doi.org/10.1016/j.crmeth.2021.100080

Ejemplares similares

Inducible de novo expression of neoantigens in tumor cells and mice with NINJA
por: Damo, Martina, et al.
Publicado: (2020)

Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
por: Pan, Jing, et al.
Publicado: (2017)

UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma
por: Kostyrko, Kaja, et al.
Publicado: (2023)

KRAS-Driven Lung Adenocarcinoma and B Cell Infiltration: Novel Insights for Immunotherapy
por: Rosamaria, Pinto, et al.
Publicado: (2019)

Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma
por: Wang, Yanxiao, et al.
Publicado: (2017)

KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy
por: Ambrogio, Chiara, et al.
Publicado: (2016)

Identification of a Clinically Relevant Signature for Early Progression in KRAS-Driven Lung Adenocarcinoma
por: Neidler, Sarah, et al.
Publicado: (2019)

Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation
por: Mukhopadhyay, Suman, et al.
Publicado: (2015)

IKKβ Kinase Promotes Stemness, Migration, and Invasion in KRAS-Driven Lung Adenocarcinoma Cells
por: Rodrigues, Felipe Silva, et al.
Publicado: (2020)

FAM111B enhances proliferation of KRAS‐driven lung adenocarcinoma by degrading p16
por: Kawasaki, Keisuke, et al.
Publicado: (2020)

Iron out KRAS-driven cancer
por: Lei, Guang, et al.
Publicado: (2022)

KRAS-driven ROS promote malignant transformation
por: Suh, Yongjoon, et al.
Publicado: (2015)

Twists and turns in Kras-driven tumor initiation
por: Maru, Yoshiaki, et al.
Publicado: (2021)

Nf1 loss promotes Kras‐driven lung adenocarcinoma and results in Psat1‐mediated glutamate dependence
por: Wang, Xiaojing, et al.
Publicado: (2019)

PPDPF Promotes the Development of Mutant KRAS‐Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1
por: Ni, Qian‐Zhi, et al.
Publicado: (2022)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

Divergent immune landscapes of primary and syngeneic Kras-driven mouse tumor models
por: Gutierrez, Wade R., et al.
Publicado: (2021)

Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS(G12D)-driven lung adenocarcinoma
por: Baltanás, Fernando C., et al.
Publicado: (2023)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
por: Arner, Emily N., et al.
Publicado: (2019)

Brown Tumors Belong to the Spectrum of KRAS-driven Neoplasms
por: Turek, Daniel, et al.
Publicado: (2022)

KRAS-related noncoding RNAs in pancreatic ductal adenocarcinoma
por: Yu, Shuang-Ni, et al.
Publicado: (2016)

Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma
por: Grinshpun, Albert, et al.
Publicado: (2019)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma
por: Gupta, Kshama, et al.
Publicado: (2022)

Distinct serum metabolomics profiles associated with malignant progression in the Kras(G12D) mouse model of pancreatic ductal adenocarcinoma
por: LaConti, Joseph J, et al.
Publicado: (2015)

Targeting copper metabolism to defeat KRAS-driven colorectal cancer
por: Aubert, Léo, et al.
Publicado: (2020)

Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
por: Hyun, Soonsil, et al.
Publicado: (2021)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Aspirin-Triggered Resolvin D1 Reduces Proliferation and the Neutrophil to Lymphocyte Ratio in a Mutant KRAS-Driven Lung Adenocarcinoma Model
por: Vannitamby, Amanda, et al.
Publicado: (2021)

Chromatin accessibility uncovers KRAS-driven FOSL2 promoting pancreatic ductal adenocarcinoma progression through up-regulation of CCL28
por: Zhang, Shujun, et al.
Publicado: (2023)

PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells
por: Huang, Zhangsen, et al.
Publicado: (2021)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
por: Stefanius, Karoliina, et al.
Publicado: (2011)

KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma
por: PALIOGIANNIS, PANAGIOTIS, et al.
Publicado: (2014)

Frequency and Spectrum of KRAS Mutations in Moroccan Patients with Lung Adenocarcinoma
por: Elghissassi, Ibrahim, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ec53mci0mtpdruo468qodj4fi3